Clinical Trial

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-01-30; most recent amendment 2026-06-15.
Status change: Completed → Active, Not Recruiting 2025-01-29
Status change: Active, Not Recruiting → Completed 2025-01-27
Status change: Recruiting → Active, Not Recruiting 2023-06-14
Status change: Not Yet Recruiting → Recruiting 2020-03-06
Trial Details
NCT Number NCT04251117
Lead Sponsor Geneos Therapeutics
Conditions HCC
Enrollment 36 participants
Start Date 2020-03-01
Primary Completion 2024-11-29 (estimated)
Study Completion 2028-11-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-22